- Home
- BROS vs ROIV Comparison
BROS vs ROIV Comparison
Compare BROS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BROS
- ROIV
- Stock Information
- Founded
- BROS 1992
- ROIV 2014
- Country
- BROS United States
- ROIV United Kingdom
- Employees
- BROS N/A
- ROIV N/A
- Industry
- BROS Restaurants
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- BROS Consumer Discretionary
- ROIV Health Care
- Exchange
- BROS Nasdaq
- ROIV Nasdaq
- Market Cap
- BROS 9.0B
- ROIV 7.8B
- IPO Year
- BROS 2021
- ROIV N/A
- Fundamental
- Price
- BROS $63.88
- ROIV $11.36
- Analyst Decision
- BROS Strong Buy
- ROIV Buy
- Analyst Count
- BROS 17
- ROIV 4
- Target Price
- BROS $78.18
- ROIV $17.50
- AVG Volume (30 Days)
- BROS 2.5M
- ROIV 7.8M
- Earning Date
- BROS 08-06-2025
- ROIV 08-07-2025
- Dividend Yield
- BROS N/A
- ROIV N/A
- EPS Growth
- BROS 109.32
- ROIV N/A
- EPS
- BROS 0.38
- ROIV N/A
- Revenue
- BROS $1,361,068,000.00
- ROIV $29,053,000.00
- Revenue This Year
- BROS $26.23
- ROIV $3.28
- Revenue Next Year
- BROS $24.06
- ROIV $156.84
- P/E Ratio
- BROS $166.75
- ROIV N/A
- Revenue Growth
- BROS 30.42
- ROIV N/A
- 52 Week Low
- BROS $26.96
- ROIV $8.73
- 52 Week High
- BROS $86.88
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- BROS 39.69
- ROIV 52.70
- Support Level
- BROS $62.86
- ROIV $10.71
- Resistance Level
- BROS $65.08
- ROIV $11.58
- Average True Range (ATR)
- BROS 2.20
- ROIV 0.31
- MACD
- BROS -0.55
- ROIV 0.02
- Stochastic Oscillator
- BROS 12.35
- ROIV 60.93
About BROS Dutch Bros Inc.
Dutch Bros Inc is an operator and franchisor of drive-thru coffee shops that are focused on serving hand-crafted beverages. The company's hand-crafted beverage-focused lineup features hot and cold espresso-based beverages, cold brew coffee products, proprietary energy drinks, tea, lemonade, smoothies and other beverages. The company has two reportable operating segments Company-operated shops and Franchising. It derives maximum revenue from Company operated shops.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.